These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15894660)

  • 1. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors.
    Collett K; Stefansson IM; Eide J; Braaten A; Wang H; Eide GE; Thoresen SØ; Foulkes WD; Akslen LA
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1108-12. PubMed ID: 15894660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.
    Kirsh VA; Chiarelli AM; Edwards SA; O'Malley FP; Shumak RS; Yaffe MJ; Boyd NF
    J Natl Cancer Inst; 2011 Jun; 103(12):942-50. PubMed ID: 21540443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
    Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
    Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast carcinoma with basal phenotype: mammographic findings.
    Luck AA; Evans AJ; James JJ; Rakha EA; Paish EC; Green AR; Ellis IO
    AJR Am J Roentgenol; 2008 Aug; 191(2):346-51. PubMed ID: 18647900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mammographic correlations with Basal-like phenotype of invasive breast cancer.
    Wang X; Chao L; Chen L; Ma G; Jin G; Hua M; Zhou G
    Acad Radiol; 2010 Mar; 17(3):333-9. PubMed ID: 19962918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Missed and true interval and screen-detected breast cancers in a population based screening program.
    Hoff SR; Samset JH; Abrahamsen AL; Vigeland E; Klepp O; Hofvind S
    Acad Radiol; 2011 Apr; 18(4):454-60. PubMed ID: 21216632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens.
    Hofvind S; Møller B; Thoresen S; Ursin G
    Int J Cancer; 2006 Jun; 118(12):3112-7. PubMed ID: 16395702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain.
    Domingo L; Sala M; Servitja S; Corominas JM; Ferrer F; Martínez J; Macià F; Quintana MJ; Albanell J; Castells X
    Cancer Causes Control; 2010 Aug; 21(8):1155-64. PubMed ID: 20349271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.
    Rayson D; Payne JI; Abdolell M; Barnes PJ; MacIntosh RF; Foley T; Younis T; Burns A; Caines J
    Clin Breast Cancer; 2011 Mar; 11(1):27-32. PubMed ID: 21421519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
    Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
    Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biennial versus annual mammography and the risk of late-stage breast cancer.
    White E; Miglioretti DL; Yankaskas BC; Geller BM; Rosenberg RD; Kerlikowske K; Saba L; Vacek PM; Carney PA; Buist DS; Oestreicher N; Barlow W; Ballard-Barbash R; Taplin SH
    J Natl Cancer Inst; 2004 Dec; 96(24):1832-9. PubMed ID: 15601639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening-detected breast cancers: discordant independent double reading in a population-based screening program.
    Hofvind S; Geller BM; Rosenberg RD; Skaane P
    Radiology; 2009 Dec; 253(3):652-60. PubMed ID: 19789229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between mammographic breast density and breast cancer tumor characteristics.
    Aiello EJ; Buist DS; White E; Porter PL
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):662-8. PubMed ID: 15767347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary approaches to assessing risk factors for interval breast cancer.
    Lowery JT; Byers T; Hokanson JE; Kittelson J; Lewin J; Risendal B; Singh M; Mouchawar J
    Cancer Causes Control; 2011 Jan; 22(1):23-31. PubMed ID: 20978835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers.
    Porter PL; El-Bastawissi AY; Mandelson MT; Lin MG; Khalid N; Watney EA; Cousens L; White D; Taplin S; White E
    J Natl Cancer Inst; 1999 Dec; 91(23):2020-8. PubMed ID: 10580027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using mammographic density to improve breast cancer screening outcomes.
    Kavanagh AM; Byrnes GB; Nickson C; Cawson JN; Giles GG; Hopper JL; Gertig DM; English DR
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2818-24. PubMed ID: 18843028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers.
    Crosier M; Scott D; Wilson RG; Griffiths CD; May FE; Westley BR
    Clin Cancer Res; 1999 Oct; 5(10):2682-8. PubMed ID: 10537329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic characteristics of interval and screen-detected breast cancers.
    Gilliland FD; Joste N; Stauber PM; Hunt WC; Rosenberg R; Redlich G; Key CR
    J Natl Cancer Inst; 2000 May; 92(9):743-9. PubMed ID: 10793111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How basal are triple-negative breast cancers?
    Bertucci F; Finetti P; Cervera N; Esterni B; Hermitte F; Viens P; Birnbaum D
    Int J Cancer; 2008 Jul; 123(1):236-40. PubMed ID: 18398844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.